Statement: the pcr of the patient cohorts is not measured in both the primary clinical trial and the secondary clinical trial.
Primary_evidence: Outcome Measurement:    Number of Patients With Pathological Complete Response Rate   Pathologic complete response (pCR), commonly defined as the absence of residual invasive cancer in both the breast and axillary lymph nodes, has emerged as a surrogate endpoint for disease-free and overall survival, as the achievement of a pCR is associated with a favorable long-term prognosis in all breast cancer subtypes.   Time frame: pre-study pathology vs. post-chemo surgery pathology (approx. 39-42 weeks post-randomization) Results 1:    Arm/Group Title: Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G))   Arm/Group Description: Received intravenous (IV) administration of nabpaclitaxel 100 mg/m2 IV weekly for 12 weeks (nP x 12) with IV bevacizumab 10 mg/kg every 2 weeks (six doses), followed by IV doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 with pegfilgrastim 6 mg subcutaneously every 2 weeks for six cycles (ddAC x 6).   Overall Number of Participants Analyzed: 98   Measure Type: Count of Participants   Unit of Measure: Participants  35  35.7% Results 2:    Arm/Group Title: Arm 2/3 (Nab-Paclitaxel/AC+PEG-G))   Arm/Group Description: Received nP x 12 followed by ddAC x 6, or received ddAC x 6 first followed by nP x 12, without bevacizumab   Overall Number of Participants Analyzed: 113   Measure Type: Count of Participants   Unit of Measure: Participants  24  21.2%
Secondary_evidence: Outcome Measurement:    Disease Free Survival.   Time to first event where an event is any recurrences, 2nd primary or death to determine the percentage of patients disease free at 8 years   Time frame: 8 years Results 1:    Arm/Group Title: Arm 1: Clodronate   Arm/Group Description: Patient receives 2 tablets once daily for 3 years.   clodronate: 1600 mg PO daily   Overall Number of Participants Analyzed: 1655   Measure Type: Number   Unit of Measure: percentage of patients  81.0 Results 2:    Arm/Group Title: Arm 2: Placebo   Arm/Group Description: Patient receives 2 tablets once daily for 3 years.   placebo: 2 pills PO daily   Overall Number of Participants Analyzed: 1656   Measure Type: Number   Unit of Measure: percentage of patients  79.6